Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders.
Agata PastorczakAndishe AttarbaschiSimon BomkenArndt BorkhardtJutte van der Werff Ten BoschSarah ElitzurAndrew R GenneryEva HlavackovaArpád KerekesZdenka KřenováWojciech MlynarskiShaji K KumarTessa WassenbergJan LoeffenPublished in: Cancers (2022)
Patients with double stranded DNA repair disorders (DNARDs) (Ataxia Telangiectasia (AT) and Nijmegen Breakage syndrome (NBS)) are at a very high risk for developing hematological malignancies in the first two decades of life. The most common neoplasms are T-cell lymphoblastic malignancies (T-cell ALL and T-cell LBL) and diffuse large B cell lymphoma (DLBCL). Treatment of these patients is challenging due to severe complications of the repair disorder itself (e.g., congenital defects, progressive movement disorders, immunological disturbances and progressive lung disease) and excessive toxicity resulting from chemotherapeutic treatment. Frequent complications during treatment for malignancies are deterioration of pre-existing lung disease, neurological complications, severe mucositis, life threating infections and feeding difficulties leading to significant malnutrition. These complications make modifications to commonly used treatment protocols necessary in almost all patients. Considering the rarity of DNARDs it is difficult for individual physicians to obtain sufficient experience in treating these vulnerable patients. Therefore, a team of experts assembled all available knowledge and translated this information into best available evidence-based treatment recommendations.
Keyphrases
- end stage renal disease
- diffuse large b cell lymphoma
- chronic kidney disease
- ejection fraction
- newly diagnosed
- dna repair
- prognostic factors
- risk factors
- peritoneal dialysis
- multiple sclerosis
- primary care
- healthcare
- palliative care
- radiation therapy
- clinical practice
- radiation induced
- blood brain barrier
- social media
- brain injury
- quality improvement
- dna damage response
- drug induced
- replacement therapy